GCGilberto Castañeda-Hernández

Gilberto Castañeda-Hernández

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gilberto Castañeda-Hernández has a total of 228 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Mexico regulates tissue transfers abroad for population genomics

    by María T. Hernández-Huerta, Gilberto Castañeda-Hernández, Hector A. Cabrera-Fuentes


  • Open Access

    Strengthening Pharmacovigilance in Latin America: Multidisciplinary Insights from Two ISoP Latin American Chapter Symposia

    by Jessica Liliana Vargas-Neri, Angela Caro-Rojas, Gilberto Castañeda-Hernández, Christian Camilo Cuello-Meza, Betty Duarte, Daniela Fontana, Cinthya Galicia-Quintanar, Victoria Hall-Ramírez, Diego Salas, Maribel Salas, et al.

    Pharmacovigilance in Latin America has witnessed notable progress in recent years, marked by advancements in regulatory frameworks, regional cooperation, and increased academic involvement. However, heterogeneity among countries, uneven institutional development, and limited resources still hinder its full impact on public health. In this context, the Latin American Chapter of the International Society of Pharmacovigilance (ISoP LATAM) has played a key role in organizing two regional symposia: Cartagena, Colombia (2023), and Merida, Mexico (2025). Through multidisciplinary roundtables and open forums, ISoP LATAM has brought together regulators, academia, healthcare professionals, researchers, patient organizations, and industry representatives to promote dialogue, identify opportunities, and propose measures to improve pharmacovigilance in the region. Discussion included regulatory harmonization and convergence, the adoption of international standards for risk management and safety reporting, and the integration of artificial intelligence and real-world evidence into pharmacovigilance systems. Participants emphasized the importance of addressing medication errors through a Human Factors/Ergonomics approach, strengthening the monitoring and regulation of biosimilars, and creating differentiated frameworks for recognizing therapeutic failures. The expansion of pharmaceutical care and the systematic inclusion of pharmacovigilance education across the health sciences’ curriculum were highlighted as priorities. The reflections from these symposia emphasize the crucial role of ISoP LATAM in providing a platform for open and multidisciplinary discussions. Shifting the focus from solely regulatory topics to a broader public health perspective and expanding the agenda to include emerging fields such as pharmacogenomics, ecopharmacovigilance, and patient engagement—while ensuring fair access to technological innovations—will be vital for enhancing drug safety in Latin America.

  • Open Access

    Introducing an In Vivo Protocol to Evaluate Skin Penetration of Topical Drugs: Proof-of-Concept with Naproxen in Humans

    by Mariannela C. Ruiz-Ruiz, María de Lourdes González-Flores, Ruth Vázquez-Román, Juan Miguel Jiménez-Andrade, Hector A. Cabrera-Fuentes, Gilberto Castañeda-Hernández


  • Open Access

    Peripheral Antinociception Induced by Carvacrol in the Formalin Test Involves the Opioid Receptor-NO-cGMP-K+ Channel Pathway

    by Mario I. Ortiz, Raquel Cariño-Cortés, Eduardo Fernández-Martínez, Victor Manuel Muñoz-Pérez, Gilberto Castañeda-Hernández, Martha Patricia González-García

    Background/Objectives: Carvacrol is a naturally occurring phenolic monoterpene that is one of the main constituents of the essential oils of oregano (Origanum vulgare) and other herbs. Carvacrol has anti-inflammatory and antinociceptive effects. Carvacrol can activate and inhibit several second messengers and ionic channels at the systemic level. However, there is no evidence of the peripheral antinociception of carvacrol and its mechanism of action. This study was designed to determine whether the opioid receptor-nitric oxide (NO)-cyclic guanosine monophosphate (cGMP)-K+ channel pathway is involved in the local antinociception of carvacrol. Methods: Wistar rats were injected with 1% formalin subcutaneously on the dorsal surface of the right hind paw with the vehicle or carvacrol (100–300 µg/paw). To determine whether the opioid receptor-NO-cGMP-K+ channel pathway and a biguanide-dependent mechanism are responsible for the local antinociception induced by carvacrol, the effect of the injection (10 min before the 1% formalin injection) with the corresponding vehicles, metformin, naltrexone, NG-L-nitro-arginine methyl ester (L-NAME), 1 H-(1,2,4)-oxadiazolo (4,2-a) quinoxalin-1-one (ODQ), and K+ channel blockers on the antinociception induced by local carvacrol (300 µg/paw) was determined. Results: In both phases of the formalin test, carvacrol produced antinociception. Naltrexone, metformin, L-NAME, ODQ, glibenclamide and glipizide (both ATP-sensitive K+ channel blockers), tetraethylammonium and 4-aminopyridine (voltage-gated K+ channel blockers), and apamin and charybdotoxin (Ca2+-activated K+ channel blockers) reversed the carvacrol-induced peripheral antinociception. Conclusions: The local peripheral administration of carvacrol produced significant antinociception and activated the opioid receptor-NO-cGMP-K+ channel pathway.


  • Open Access

    Antioxidative Action of Alpha-Linolenic Acid during Its Gastroprotective Effect in an Indomethacin-Induced Gastric Injury Model

    by Cristina Salinas-Nolasco, Elizabeth Pérez-Hernández, Secilia Garza, Hui Gyu Park, J. Thomas Brenna, Gilberto Castañeda-Hernández, César A.S. Reyes-López, Nury Pérez-Hernández, Aracely Evangelina Chávez-Piña

    Cristina Salinas-Nolasco, Elizabeth Pérez-Hernández, Secilia Garza, Hui Gyu Park, J. Thomas Brenna, Gilberto Castañeda-Hernández, César A.S. Reyes-López, Nury Pérez-Hernández, and Aracely Evangelina Chávez-Piña. Prev Nutr Food Sci 2025;30:132-40. https://doi.org/10.3746/pnf.2025.30.2.132


  • Open Access

    Peripheral Antinociception Induced by Carvacrol in the Formalin Test Involves the Opioid Receptor-NO-cGMP-K+ Channels Pathway

    by Mario I. Ortiz, Raquel Cariño-Cortés, Eduardo Fernández-Martínez, Victor Manuel Muñoz-Pérez, Gilberto Castañeda-Hernández, Martha Patricia González-García

    Background/Objectives: Carvacrol is a naturally occurring phenolic monoterpene that is one of the major constituents of the essential oils of oregano (Origanum vulgare), thyme (Thymus vulgaris) and other herbs. Carvacrol has anti-inflammatory and antinociceptive effects. At the systemic level, carvacrol is able to activate and inhibit several second messengers and ion channels. However, there is no evidence on the peripheral antinociception of carvacrol and its probable mechanism of action. The aim of this study was to investigate whether the local antinociception of carvacrol involves the opioid receptor-nitric oxide (NO)-GMP-K+ channel pathway. Methods: Formalin (1%) was injected into the dorsal surface of the right hind paw of Wistar rats. Rats received a subcutaneous injection into the dorsal surface of the paw of vehicle or carvacrol (100-300 µg/paw). To determine whether the local antinociception induced by carvacrol was mediated by the opioid receptor-NO-cGMP-K+ channel pathway and a biguanide-dependent mechanism, the effect of pretreatment (10 min before formalin injection) with the corresponding vehicles, naltrexone, L-NAME, 1 H-(1,2,4)-oxadiazolo (4,2-a) quinoxalin-1-one (ODQ), K+ channel blockers, and metformin on the antinociceptive effects induced by local carvacrol (300 µg/paw) were evaluated. Results: Carvacrol produced antinociception during both phases of the formalin test. Naltrexone, L-NAME, ODQ, glibenclamide and glipizide (both ATP-sensitive K+ channel blockers), tetraethylammonium and 4-aminopyridine (both voltage-gated K+ channel blockers), apamin and charybdotoxin (both Ca2+-activated K+ channel blockers), and metformin reversed the carvacrol-induced peripheral antinociception. Conclusions: Local peripheral administration of carvacrol was able to produce significant antinociception and activate the opioid receptor-NO-cGMP-K+ channel pathway. In addition, carvacrol activated a metformin-dependent mechanism at the peripheral level.

  • Recommendations for Interchangeability in a Growing Biosimilar Market in Latin America

    by Gilberto Castañeda-Hernández, Manuel Antonio Espinoza, Luis Eduardo Pino, Mariana Rico-Restrepo, Bianca Schiavetti, Enrique Terán, Valderilio Feijo Azevedo

    Background Biosimilars offer significant advantages for improving access to biologic treatments in Latin America. However, their uptake has been slow due to misconceptions, regulatory uncertainties, and inadequate pharmacovigilance. Objective To address these issues, Americas Health Foundation convened a multidisciplinary panel of regional experts in biosimilar use and interchangeability from Latin America. The panel assessed the current landscape and recommended steps to enhance access. Results Key recommendations include strengthening biosimilar regulations, ensuring transparent enforcement, implementing robust pharmacovigilance, and promoting collaboration among stakeholders to educate about the safety, efficacy, and economic advantages of biosimilars and their interchangeability. Conclusions By embracing biosimilars and interchangeability, Latin American countries can expand patient access, foster competition, diversify treatment sources, and enhance the sustainability of their healthcare systems. However, achieving these goals requires addressing knowledge gaps and biases among healthcare providers, patients, regulators, and government agencies. This can be accomplished through clear communication and the use of real-world evidence.


  • Open Access

    Selecting the best-value biosimilar in emerging countries

    by Gilberto Castañeda-Hernández

    The aim of biosimilars is to alleviate the financial burden of biological medicinal products. A most relevant challenge for emerging countries is how to select the best option available. In most cases, price is the major determinant, as budgets are chronically scarce. However, initial savings due to price reductions can be overridden if there is a lack of supply due to product shortages or withdrawals. These events can be prevented by a best-value strategy. According to the concept of best-value medicinal products, price is only one of the various criteria to be considered. The purpose of the present paper is to provide suggestions of criteria that can be useful for selecting the best-value biological in emerging countries. Six criteria, that are not limitative, have been selected as follows: standards of regulatory approval, quality of the product, good distribution practices, security of supply, pharmacovigilance, and price.


  • Open Access

    Appropriateness of Ketoanalogues of Amino Acids, Calcium Citrate, and Inulin Supplementation for CKD Management: A RAND/UCLA Consensus

    by Nadia Saavedra-Fuentes, Enrique Carmona-Montesinos, Gilberto Castañeda-Hernández, Israel Campos, Juan Carlos Castillo-Salinas, Javier Alberto Castillo-Tapia, Karla Guadalupe Del Castillo-Loreto, Juan Carlos Falcón-Martínez, Raquel Fuentes-García, Miguel Ángel García de León Guerrero, et al.

    Background: Current treatment for chronic kidney disease (CKD) focuses on improving manifestations and delaying progression. Nutritional approaches play a crucial role in CKD management, and various supplements have become available. Ketoanalogues of amino acids (KAs), calcium citrate, and inulin have been proposed as suitable supplements, yet their widespread use has been limited due to insufficient evidence. This study aimed to generate general guidance statements on the appropriateness of these supplements through a RAND/UCLA consensus process. Methods: A RAND/UCLA consensus panel was convened to evaluate the appropriateness of these supplements in different clinical scenarios. In this study, we present a subgroup analysis focusing on a panel of eleven clinical nephrologists from among the experts. Results: Supplementation of low-protein diets (LPDs) and very low-protein diets (VLPDs) with KA was considered appropriate to reduce manifestations and delay CKD outcomes, supplementation with calcium citrate is considered appropriate to reduce CKD manifestations, and supplementation with inulin is considered appropriate to delay CKD outcomes and manage comorbidities. Conclusions: Based on a combination of clinical experience and scientific evidence, the panel reached a consensus that KA supplementation of LPD and VLPD, calcium citrate, and inulin are appropriate in patients with CKD across various scenarios.


  • Open Access

    Appropriateness of Ketoanalogues of Aminoacids, Calcium Citrate, and Inulin Supplementation for CKD Management: A RAND/UCLA Consensus

    by Nadia Saavedra-Fuentes, Enrique Carmona-Montesinos, Gilberto Castañeda-Hernández, Israel Campos, Juan Carlos Castillo-Salinas, Javier Alberto Castillo-Tapia, Karla Guadalupe Del Castillo-Loreto, Juan Carlos Falcón-Martínez, Raquel Fuentes-García, Miguel Ángel García de León Guerrero, et al.

    Background: Current treatment for Chronic Kidney Disease (CKD) focuses on improving manifestations and delaying progression. Nutritional approaches play a crucial role in CKD management, and various supplements have become available. Ketoanalogues of amino acids (KA), calcum citrate, and inulin have been proposed as suitable supplements, yet their widespread use has been limited due to insufficient evidence. This study aimed to generate general guidance statements on the appropriateness of these supplements through a RAND/UCLA consensus process; Methods: A RAND/UCLA consensus panel was convened to evaluate the appropriateness of these supplements in different clinical scenarios. In this study, we present a subgroup analysis focusing on a panel of eleven clinical nephrologists from among the experts; Results: Supplementation of low protein diets (LPD) and very low protein diets (VLPD) with KA was considered appropriate to reduce manifestations and delay CKD outcomes, supplementation with calcium citrate is considered appropriate to reduce CKD manifestations, and supplementation with inulin is considered appropriate to delay CKD outcomes and manage comorbidities; Conclusions: Based on a combination of clinical experience and scientific evidence , the panel reached a consensus that KA supplementation of LPD and VLPD, calcium citrate, and inulin are appropriate in patients with CKD across various scenarios.